AI medical service
AI Medical Service signs joint research agreement with Mahidol University, Thailand
~First case of joint research with a Japanese company in the field of gastrointestinal endoscopy AI~
……
AI Medical Service Co., Ltd. (Headquarters: Toshima-ku, Tokyo, Representative Director and CEO: Tomohiro Tada, hereinafter referred to as “AIM”), which develops AI (artificial intelligence) that supports image diagnosis for endoscopes, and Mahidol University (location: 999 Phuttamonthon, Thailand) 4 Road, Salaya, Nakhon Pathom 73170 Thailand (hereinafter “Mahidol”) has concluded a joint research agreement on March 1, 2024, and will begin joint research on endoscope AI from April 1, 2024. Masu.
This is the first time that AIM has concluded a joint research agreement with a Japanese company in the field of gastrointestinal endoscopy AI (Note 1).
[Image 1: https://prtimes.jp/i/49025/27/resize/d49025-27-606e067169d6df15ed9e-0.png&s3=49025-27-06c71e82f1ac0b3f41686c3d5a6ff387-3900×1063.png ]
■Content and purpose of joint research
AIM will begin joint research with Mahidol University to verify the practicality of endoscopic AI in Thailand.
AIM is an AI-equipped endoscopic image diagnosis support system that will be launched in Japan in December 2023 to assist doctors in diagnosis by detecting lesion candidates that should be considered for additional tests such as biopsy based on macroscopic characteristics during endoscopy. We have obtained manufacturing and sales approval for the product, and sales will begin in March 2024. Additionally, in February 2024, we completed medical device registration in Singapore for an endoscopic image diagnosis support system that determines whether gastric lesions are neoplastic or non-neoplastic.
AIM aims to deploy our products not only in Japan but also in clinical settings around the world, and through this research we will verify whether the AI model developed using Japanese case data can be effectively used in Thailand.
Mahidol, with which we will conduct joint research, is one of the most prestigious universities in Thailand, established in 1888, and conducts education and research in a wide range of fields, including medicine, science, veterinary medicine, engineering, and the humanities. It is Thailand’s top comprehensive national university. Through joint research with Mahidol, AIM will explore the possibility of using endoscopic AI in clinical settings in Thailand.
■Comment from Tomohiro Tada, Representative Director and CEO We are very happy to begin joint research on gastric cancer endoscopy AI with Mahidol University, one of Thailand’s leading universities. In Asia, the number of patients and deaths from gastric cancer is high, and the detection of cancer at an early stage is a serious issue that needs to be addressed. Treatment is required. AI Medical Service will work on this joint research in order to deliver endoscopic AI, which is the crystallization of Japan’s world-leading knowledge and track record in endoscopic medical care, to clinical sites in Thailand as soon as possible.
■Comments from Dr. Jirawat Swangsri
[Image 2: https://prtimes.jp/i/49025/27/resize/d49025-27-5da7ab048c7615c50ad7-1.jpg&s3=49025-27-48712bb8ad1a656bf33255ca46e576fa-1796×2700.jpg] Career:
Assistant Prof. Jirawat Swangsri MD.Ph.D.
Division of Minimally Invasive Surgery
Department of Surgery
Siriraj Hospital Mahidol University
Original comment:
“We are excited to begin collaborating with AIM, the world leader in research and development of endoscopic AI.
As you know esophageal cancer and gastric cancer cases are on the rise. The early detection and early treatment to the upper GI malignant would gain better survival and quality of life. In our country, the diagnosis of these GI cancers at an early stage is difficult for both training and clinical practice. We hope that AIM’s technology will be impact on clinical challenges and improve Thailand health care standard in near future.”
Comment translation:
“We are very excited to begin our collaboration with AIM, a world leader in research and development in the field of endoscopy AI. As you know, esophageal cancer and gastric cancer are increasing year by year, and early detection and treatment of neoplastic lesions leads to improved survival rates and quality of life. However, in Thailand, it is currently difficult to diagnose such lesions at an early stage, both in training and clinical practice. We hope that AIM’s technology will support the resolution of clinical issues in Thailand in the near future and lead to improved medical standards in Thailand. ” ■About AI medical service
AIM is a medical AI startup company with the mission of “Saving patients around the world – Eliminate missed cancers with endoscopic AI”. Japan is at the cutting edge of endoscopic medical care, and has accumulated the world’s highest level of data in terms of both quality and quantity. In particular, AIM is conducting joint research and product development with over 100 medical facilities. By quickly delivering endoscopic AI to medical settings, we aim to reduce the number of missed cases of cancer and save patients around the world. ■About Tomohiro Tada, Representative Director and CEO
[Image 3: https://prtimes.jp/i/49025/27/resize/d49025-27-80e88115504703062b76-2.jpg&s3=49025-27-595a8a1278313dea24e875d8544a18d2-3000×2000.jpg] Tomohiro Tada, Doctor of Medicine
[Affiliation/Position]
AI Medical Service Co., Ltd. Representative Director and CEO Chairman of Medical Corporation Tomohiro Gastroenterology and Proctology [Summary]
Graduated from the Department of Medicine, Faculty of Medicine, University of Tokyo in 1996. Worked as a surgical resident at the University of Tokyo Hospital. Completed doctoral course at the University of Tokyo Graduate School of Medicine in 2005. In 2006, he opened Tomohiro Gastroenterology and Proctology. Since 2012, he has been a visiting lecturer at the Department of Oncology Surgery, Faculty of Medicine, University of Tokyo. Established AI Medical Service Co., Ltd. in 2017 and assumed the position of Representative Director and CEO, where he remains today.
■Past efforts toward overseas expansion
You can check our past efforts toward overseas expansion here (https://www.ai-ms.com/news/global).
Company Profile